☆ 4.7 Editorial Material

A PHD inhibitor prevents changes in the phosphoproteome and capillary rarefaction by CsA: treatment option for CKD?

KIDNEY INTERNATIONAL (2022)

Related references

Note: Only part of the references are listed.

Article Urology & Nephrology

Daprodustat prevents cyclosporine-A-mediated anemia and peritubular capillary loss

Robert Labes et al.

Summary: This study demonstrates that the hypoxia inducible factor activator daprodustat can prevent the protein phosphorylation changes caused by Cyclosporine-A, and has a protective effect on microcirculation, hemoglobin concentration, and kidney capillary density.

KIDNEY INTERNATIONAL (2022)

Add to Collection

Review Transplantation

Hypoxia in chronic kidney disease: towards a paradigm shift?

Anna Faivre et al.

Summary: Chronic kidney disease (CKD) is defined as an alteration of kidney structure and/or function lasting for >3 months, affecting 10% of the general adult population. The role of hypoxia in CKD progression has been controversially discussed since the end of the last century.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

Add to Collection

Review Biochemistry & Molecular Biology